David S. Ziegler

Anti-apoptosis mechanisms in malignant gliomas.

Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy.

Outcomes in multifocal neuroblastoma as part of the neurocristopathy syndrome.

Never say never.

Case Report of Spontaneous Resolution of a Congenital Glioblastoma.

Too many targets, not enough patients: rethinking neuroblastoma clinical trials.

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.

International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Correction to: International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma.

Predictors of Success of Phase II Pediatric Oncology Clinical Trials.

Piloting a parent and patient decision aid to support clinical trial decision making in childhood cancer.

Translating palbociclib to the clinic for DIPG - What is truly achievable?

"Balancing Expectations with Actual Realities": Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial.

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer.

Recurrent fusions in pediatric sarcoma and brain tumors.

Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.

Frontiers in the treatment of glioblastoma: Past, present and emerging.

Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas.

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor.

Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.

The important role of routine cytopathology in pediatric precision oncology.

Parents' experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvements.

Diffuse leptomeningeal glioneuronal tumour (DLGNT) in children: the emerging role of genomic analysis.

In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.

Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.

Parents' understanding of genome and exome sequencing for pediatric health conditions: a systematic review.

What's in a Name? Parents' and Healthcare Professionals' Preferred Terminology for Pathogenic Variants in Childhood Cancer Predisposition Genes.

The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science.

Quality of Life (QoL) of Children and Adolescents Participating in a Precision Medicine Trial for High-Risk Childhood Cancer.

Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes.

From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer.

loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma.

Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.

A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer.

LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.

BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience.

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial.

Parents' and adolescents' perspectives and understanding of information about childhood cancer precision medicine.

Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.

Precision Medicine Is Changing the Roles of Healthcare Professionals, Scientists, and Research Staff: Learnings from a Childhood Cancer Precision Medicine Trial.

Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors: The AIM BRAIN Project: An Australian and New Zealand Children's Haematology/Oncology Group Study.

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer.

Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.

Hopes, concerns, satisfaction and regret in a precision medicine trial for childhood cancer: a mixed-methods study of parent and patient perspectives.

Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.

A paradigm shift in how we treat pediatric low-grade glioma-Targeting the molecular drivers.

Communicating with families of young people with hard-to-treat cancers: Healthcare professionals' perspectives on challenges, skills, and training.

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.

A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.

Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.

Co-design of a paediatric oncology medicines database (ProCure) to support complex care provision for children with a hard-to-treat cancer.

Development of Orthotopic Patient-Derived Xenograft Models of Pediatric Intracranial Tumors.

Precision-guided treatment in high-risk pediatric cancers.

Liver disease and transplantation in telomere biology disorders: An international multicenter cohort.

The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer.

Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201.

Barriers to access of precision guided therapies for children with high-risk cancer.

When genetics and pediatric cancer collide: Understanding and optimizing families' experiences.

Novel paediatric case of a spinal high-grade astrocytoma with piloid features in a patient with Noonan Syndrome.

Impact of time to antibiotics on clinical outcome in paediatric febrile neutropenia: a target trial emulation of 1685 episodes.

Second Opinion Seeking in Paediatric Oncology: Motivations and Predictors.

Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule Compounds.

Whatever It Takes: Parents' Perspectives of Patient-Derived Xenograft Mouse Models for Poor Prognosis Childhood Cancer.